IRSF Days 2 and 3: Recap of Conference Presentations and Mgmt Investor Dinner

Research evidence excerpt

IRSF Days 2 and 3: Recap of Conference Presentations and Mgmt Investor Dinner

C O M PA N Y N O T E

1 J u l y 2 0 2 6

Taysha Gene Therapies, Inc. (TSHA) Overweight

CONCLUSION PRICE: US$6.81

We hosted an investor dinner at IRSF with TSHA management in which the discussion was TARGET: US$12.00

broad in scope across ongoing clinical development of TSHA-102, regulatory requirements Our $12 PT is based on a DCF through

for TSHA-102 in the U.S. and ex-U.S., commercial readiness, and long-term strategic 2036E (12% discount rate) and assumes

vision. The company is on track for 6-month data and FDA feedback on FDA BLA future revenue forecasts for TSHA-102 in Rett

submission in 1H '27. Next data could be seizure control analysis from Part A at YE '26. syndrome, with total non-risk-adjusted peak

sales of $1.8B in the US and EU.

• IRSF Conference - An Inspiring Dedication to Patients and Caregivers: Over the Biren Amin

past two days, we attended several panels where patients and caregivers shared the Sr. Research Analyst, Piper Sandler & Co.

challenges faced by the Rett syndrome community. A panel of four parents offered a 732 284-6909, biren.amin@psc.com

glimpse into their daily lives; one of the parents has twin girls that are both afflicted with Michael Mazzola, Ph.D.

Rett; one of the twins had earlier onset and greater disease severity. Each parent on Research Analyst, Piper Sandler & Co.

the panel emphasized the need for treatments that can help improve communication. 212 284-9397, michael.mazzola@psc.com

One parent mentioned their child is unable to communicate, and therefore it's difficult Felicia Berben, PharmD

Research Analyst, Piper Sandler & Co. to triage medical episodes. Another highlighted improved communication could come in 212 284-9412, felicia.berben@psc.com